ClinicalTrials.gg
CompletedNCT02650973Updated Aug 1, 2016

Study to Assess the Pharmacokinetic and Pharmacodynamic Bioequivalence of CHS-1701 With Neulasta

A Phase 1 interventional study of CHS-1701 and Pegfilgrastim in Healthy, sponsored by Coherus Biosciences, Inc.. Completed at 4 sites in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-08-01.

Sponsored by Coherus Biosciences, Inc. · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
122
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

This is a randomized, single-blind, 3-period crossover study in healthy subjects to assess PK, PD, and safety (including immunogenicity) of a single 6mg subcutaneous injection of CHS-1701 (Coherus pegfligrastim) or 6mg SC dose of Neulasta (pegfilgrastim) given during each period.

Read the detailed description

This is a randomized, single-blind, 3-period crossover study in healthy subjects to assess PK, PD, and safety (including immunogenicity) of a single 6mg subcutaneous injection of CHS-1701 or 6mg SC dose of Neulasta given during each period.

The screening period may occur up to 28 days prior to the confinement period. After screening, eligible subjects will be randomly assigned to one of three possible treatment sequences. Treatments will be spaced by not less than 28 days.

02

Conditions studied

  • Healthy

Keywords

  • Bioequivalence
03

In context

Lead sponsor

Coherus Biosciences, Inc. is the lead sponsor of 11 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult male or female of ages 18 to 45 inclusive
  2. Body weight > 50 kg (110 lb.) and between 18 and 28 kg/m2 inclusive
  3. Medically healthy with clinically insignificant findings based on medical history, 12-lead , and physical examination
  4. Negative urine pregnancy test in women of

Exclusion criteria

Exclusion Criteria:

  1. Previous exposure to pegfilgrastim or filgrastim
  2. Current or previous cancer, diabetes, or any cardiovascular, metabolic, endocrine, renal, hepatic, gastrointestinal, hematologic, respiratory, dermatological, neurological, gynecologic, psychiatric, or other disorder
  3. History of chronic or acute respiratory illness within the past 3 months
  4. Positive urine drug or alcohol screen or unwillingness to abstain from alcohol or recreational drugs for the duration of study participation
  5. No prescription or nonprescription drugs during the study
  6. Participation in an clinical study within 30 days prior to screening
  7. History of known clinically significant drug and/or food allergies, including allergic reaction to latex
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
122 participants (actual)

Study arms

  • Experimental
    Sequence A

    3 doses of CHS-1701 or Neulasta, random order

    Drug: CHS-1701 · Drug: Pegfilgrastim

  • Experimental
    Sequence B

    3 doses of CHS-1701 or Neulasta, random order

    Drug: CHS-1701 · Drug: Pegfilgrastim

  • Experimental
    Sequence C

    3 doses of CHS-1701 or Neulasta, random order

    Drug: CHS-1701 · Drug: Pegfilgrastim

Interventions

06

What researchers measure

Primary outcomes

  1. Bioequivalence as measured by PK and PD

    The primary objective of this study is to assess the bioequivalence of CHS-1701 with Neulasta® based on the pharmacokinetics (PK) of pegfilgrastim and the pharmacodynamic (PD) response as measured by absolute neutrophil count (ANC)

    Time frame: 84 Days

Secondary outcomes

  1. PK Profile: Cmax

    Characterization of the PK profile of CHS-1701 using standard parameters of maximum plasma concentration (Cmax)

    Time frame: 84 Days

  2. PK Profile: tmax

    Characterization of the PK profile of CHS-1701 using standard parameters of time to maximum plasma concentration (tmax)

    Time frame: 84 Days

  3. PK Profile: AUC0-t

    Characterization of the PK profile of CHS-1701 using standard parameters of area under the plasma concentration versus time curve calculated from 0 to the last measurable observation (AUC0-t)

    Time frame: 84 Days

  4. PK Profile: t1/2

    Characterization of the PK profile of CHS-1701 using standard parameters of terminal elimination half-life (t1/2)

    Time frame: 84 Days

  5. Safety Profile as assessed by clinical adverse events (AEs), laboratory variables, vital signs, incidence of antidrug antibodies (ADAs), and local injection site reactions (ISRs)

    Characterization of the safety profile and tolerance of CHS-1701, as assessed by clinical adverse events (AEs), laboratory variables, vital signs, incidence of antidrug antibodies (ADAs), and local injection site reactions (ISRs).

    Time frame: 84 Days

07

Study locations

4 sites
  • WCCT
    Cypress, California 90630, United States
  • Medpace CPU
    Cincinnati, Ohio 45227, United States
  • ICON
    San Antonio, Texas, United States
  • Spaulding
    West Bend, Wisconsin 53095, United States
08

References and documents

Publications

  • Civoli F, Finck B, Tang H, Hodge J, O'Kelly H, Vexler V. Biosimilar Pegfilgrastim-cbqv Demonstrated Similar Immunogenicity to Pegfilgrastim in Healthy Subjects Across Three Randomized Clinical Studies. Adv Ther. 2022 Mar;39(3):1230-1246. doi: 10.1007/s12325-021-02024-x. Epub 2022 Jan 16. PubMed 35034311 ↗
  • Finck B, Tang H, Civoli F, Hodge J, O'Kelly H, Vexler V. Pharmacokinetic and Pharmacodynamic Equivalence of Pegfilgrastim-cbqv and Pegfilgrastim in Healthy Subjects. Adv Ther. 2020 Oct;37(10):4291-4307. doi: 10.1007/s12325-020-01459-y. Epub 2020 Aug 13. PubMed 32789809 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2016, a primary completion of Jun 2016 and a completion of Jun 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 5, 2016
First posted
Jan 8, 2016
Start
Feb 2016
Primary completionActual
Jun 2016
CompletionActual
Jun 2016
Last update
Aug 1, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 1, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02650973
Lead sponsor
Coherus Biosciences, Inc.
Responsible party
Sponsor
First posted
Jan 8, 2016
Start date
Feb 2016
Primary completion
Jun 2016
Completion
Jun 2016
Last update
Aug 1, 2016

Study contacts

Barbara Finck, MD
study director · Coherus BioSciences

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pegfilgrastim

Start the discussion